secwatch.observer — SEC 8-K summary
======================================

Issuer:     IGC Pharma, Inc. (IGC)
CIK:        0001326205
Form:       8-K
Filed at:   2022-04-18T23:59:59+00:00
Accession:  0001185185-22-000461
Event type: litigation
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IGC obtains final court approval of shareholder class action settlement; lawsuits dismissed
--------------------------------------------------------------------------------

- Court granted final approval of settlement on April 13, 2022, dismissing Tchatchou and Harris-Carr consolidated class actions.
- Settlement resolves all shareholder class action lawsuits pending against IGC and its officers.
- Most settlement costs paid through company's insurance policy; terms previously disclosed in Form 10-Q filed Feb 10, 2022.
- IGC continues Alzheimer's drug development with IGC-AD1, a THC-based investigational drug; Phase 2 trial planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326205/000118518522000461/0001185185-22-000461-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326205/000118518522000461/indiaglob20220418_8k.htm
  HTML page:      https://secwatch.observer/filing/0001185185-22-000461

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer